MX2012003296A - Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina. - Google Patents

Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.

Info

Publication number
MX2012003296A
MX2012003296A MX2012003296A MX2012003296A MX2012003296A MX 2012003296 A MX2012003296 A MX 2012003296A MX 2012003296 A MX2012003296 A MX 2012003296A MX 2012003296 A MX2012003296 A MX 2012003296A MX 2012003296 A MX2012003296 A MX 2012003296A
Authority
MX
Mexico
Prior art keywords
latanoprost
resin
eye drops
adsorption
aqueous eye
Prior art date
Application number
MX2012003296A
Other languages
English (en)
Inventor
Tomoko Nakajima
Wakiko Asayama
Tetsuya Tajika
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of MX2012003296A publication Critical patent/MX2012003296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee una gota ocular acuosa que contiene latanoprost, la cual es una preparación en donde la disminución de una concentración efectiva de latanoprost debida a la adsorción a una resma es suprimida, y la estabilidad de latanoprost es mejorada; es también un objetivo de la presente invención proveer un método para suprimir la adsorción de latanoprost a una resma; la presente invención provee una gota ocular acuosa que contiene latanoprost, un agente tensoactivo, y un ácido mono- o di-carboxílico alifático que tiene un número de carbonos de 3 a 10 o una sal del mismo; además, la presente invención provee un método para suprimir la adsorción de latanoprost a una resma en una solución acuosa, que incluye la adición de un agente tensoactivo, y un ácido mono- o di-carboxílico alifático que tiene un número de carbonos de 3 a 10 o una sal del mismo.
MX2012003296A 2009-09-17 2010-09-17 Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina. MX2012003296A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009216182 2009-09-17
PCT/JP2010/066263 WO2011034192A1 (ja) 2009-09-17 2010-09-17 ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法

Publications (1)

Publication Number Publication Date
MX2012003296A true MX2012003296A (es) 2012-04-20

Family

ID=43758789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003296A MX2012003296A (es) 2009-09-17 2010-09-17 Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.

Country Status (8)

Country Link
US (1) US20120184552A1 (es)
EP (1) EP2478906A4 (es)
JP (1) JPWO2011034192A1 (es)
CN (1) CN102481301A (es)
CA (1) CA2773597A1 (es)
MX (1) MX2012003296A (es)
RU (1) RU2012115103A (es)
WO (1) WO2011034192A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9968679B2 (en) 2013-01-31 2018-05-15 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP2937076B1 (en) * 2014-04-25 2019-09-11 Alfred E. Tiefenbacher (GmbH & Co. KG) Eye drops containing prostaglandin and tyloxapol
EP3145549A4 (en) * 2014-05-23 2018-02-14 Ocular Technologies Sàrl Topical formulations and uses thereof
WO2017094506A1 (ja) * 2015-11-30 2017-06-08 ロート製薬株式会社 眼科組成物
EP3423076B1 (en) 2016-02-29 2024-04-17 Sun Pharmaceutical Industries Limited Topical cyclosporine-containing formulations and uses thereof
US11331390B2 (en) 2016-04-22 2022-05-17 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
EP3446682B1 (en) * 2016-04-22 2021-05-26 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
EP3590515A4 (en) * 2017-02-28 2020-12-23 Kowa Company, Ltd. DRUG PRODUCT
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
JP6931493B2 (ja) * 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
CN110031584A (zh) * 2019-04-17 2019-07-19 银谷制药有限责任公司 Hplc法测定鲑鱼降钙素喷鼻剂中苯扎氯铵含量的方法
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286903B2 (en) * 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP0569046B1 (en) 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
CN1124842C (zh) 1997-11-05 2003-10-22 千寿制药株式会社 缓释滴眼剂
CN1146423C (zh) 1998-07-14 2004-04-21 阿尔康实验室公司 前列腺素产品
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
KR100437873B1 (ko) 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
JP4092507B2 (ja) 2003-07-31 2008-05-28 参天製薬株式会社 プロスタグランジン含有製品
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
JP4820648B2 (ja) * 2003-12-02 2011-11-24 千寿製薬株式会社 ロテプレドノールエタボネート水性懸濁液剤
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
JP5247453B2 (ja) 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009040727A (ja) 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
JP5437581B2 (ja) 2008-03-11 2014-03-12 豊興工業株式会社 油圧ユニット

Also Published As

Publication number Publication date
CN102481301A (zh) 2012-05-30
CA2773597A1 (en) 2011-03-24
EP2478906A4 (en) 2013-02-20
WO2011034192A1 (ja) 2011-03-24
US20120184552A1 (en) 2012-07-19
JPWO2011034192A1 (ja) 2013-02-14
RU2012115103A (ru) 2013-10-27
EP2478906A1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
MX2012003296A (es) Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2019001253A (es) Conjugados de proteina-agente activo y metodo para su preparacion.
MX349735B (es) Granulos de enzima.
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
MX355147B (es) Fluido para mantenimiento de pozos y metodos para el mantenimiento de un pozo con el fluido.
MX362807B (es) Formulacion estabilizada de pemetrexed.
MX359318B (es) Composiciones que comprenden polietilenglicol y ascorbato.
ZA202210899B (en) Solutons for increasing the stability and shelf life of an organ and tissue preservation solution
PH12015500702B1 (en) Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same
IN2012DN05192A (es)
WO2010088064A3 (en) Preservation of ergothioneine
GB2500128A (en) Colonoscopy-preparation
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
WO2013162933A3 (en) Active halogen antimicrobial composition and method of use
SG159481A1 (en) Stabilization of thermolysin in aqueous solution
PH12014501307A1 (en) Liquid activation system
WO2013038202A3 (en) Over-expression of gcn2-type protein kinase in plants
NZ623513A (en) Cleaning composition
NZ608164A (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof
UA48886U (ru) СПОСОБ ЛЕЧЕНИЯ ТЕЛЯТ |телят|С КАТАРАЛЬНОЙ БРОНХОПНЕВМОНИЕЙ
UA53320U (ru) Способ фармакокоррекции интоксикации летучими компонентами эпоксидных смол кофацином (ацетилцистеином)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal